Carboplatin Pfizer

Carboplatin Pfizer Mechanism of Action

carboplatin

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Full Prescribing Info
Action
Pharmacotherapeutic Group: Antineoplastic agent.
Pharmacology: Carboplatin has an inorganic heavy metal complex containing a central atom of platinum. It is an analogue of cisplatin. Carboplatin has biochemical properties similar to those of cisplatin. It is believed to bind to DNA to produce intra- and interstrand (predominantly) crosslinks which modify structure and inhibit DNA synthesis.
Pharmacokinetics: Elimination and Excretion: After intravenous infusion of a single dose over one hour, plasma concentrations of total platinum and free platinum decline biphasically following first order kinetics. For free platinum, reported value for the initial phase of the half-life (t alpha½) is about 90 minutes and in the later phase the half-life (t beta½) is about 6 hours. Total platinum elimination has a similar initial half-life, while in the later phase the half life of total platinum may be greater than 24 hours.
Carboplatin is mainly excreted by the kidneys. Most excretion occurs within the first 6 hours of administration with 50-70% excreted within 24 hours. 32% of the dose is excreted as unchanged drug. A reduction in dosage is recommended for patients with poor renal function.
Protein binding is less than with cisplatin. Initially protein binding is low, with up to 29% of carboplatin bound during the first 4 hours. After 24 hours 85-89% is protein bound.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in